Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleORIGINAL ARTICLE

Membrane Structure Modulation, Protein Kinase Cα Activation, and Anticancer Activity of Minerval

Jordi Martínez, Oliver Vögler, Jesús Casas, Francisca Barceló, Regina Alemany, Jesús Prades, Tünde Nagy, Carmela Baamonde, Philip G. Kasprzyk, Silvia Terés, Carlos Saus and Pablo V. Escribá
Molecular Pharmacology February 2005, 67 (2) 531-540; DOI: https://doi.org/10.1124/mol.104.000778
Jordi Martínez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Vögler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesús Casas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francisca Barceló
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Regina Alemany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesús Prades
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tünde Nagy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carmela Baamonde
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip G. Kasprzyk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvia Terés
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Saus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pablo V. Escribá
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Most drugs currently used for human therapy interact with proteins, altering their activity to modulate the pathological cell physiology. In contrast, 2-hydroxy-9-cis-octadecenoic acid (Minerval) was designed to modify the lipid organization of the membrane. Its structure was deduced following the guidelines of the mechanism of action previously proposed by us for certain antitumor drugs. The antiproliferative activity of Minerval supports the above-mentioned hypothesis. This molecule augments the propensity of membrane lipids to organize into nonlamellar (hexagonal HII) phases, promoting the subsequent recruitment of protein kinase C (PKC) to the cell membrane. The binding of the enzyme to membranes was marked and significantly elevated by Minerval in model (liposomes) and cell (A549) membranes and in heart membranes from animals treated with this drug. In addition, Minerval induced increased PKCα expression (mRNA and protein levels) in A549 cells. This drug also induced PKC activation, which led to a p53-independent increase in p21CIP expression, followed by a decrease in the cellular concentrations of cyclins A, B, and D3 and cdk2. These molecular changes impaired the cell cycle progression of A549 cells. At the cellular and physiological level, administration of Minerval inhibited the growth of cancer cells and exerted antitumor effects in animal models of cancer without apparent histological toxicity. The present results support the potential use of Minerval and related compounds in the treatment of tumor pathologies.

  • Received March 26, 2004.
  • Accepted November 5, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 67 (2)
Molecular Pharmacology
Vol. 67, Issue 2
1 Feb 2005
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Membrane Structure Modulation, Protein Kinase Cα Activation, and Anticancer Activity of Minerval
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleORIGINAL ARTICLE

Membrane Structure Modulation, Protein Kinase Cα Activation, and Anticancer Activity of Minerval

Jordi Martínez, Oliver Vögler, Jesús Casas, Francisca Barceló, Regina Alemany, Jesús Prades, Tünde Nagy, Carmela Baamonde, Philip G. Kasprzyk, Silvia Terés, Carlos Saus and Pablo V. Escribá
Molecular Pharmacology February 1, 2005, 67 (2) 531-540; DOI: https://doi.org/10.1124/mol.104.000778

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleORIGINAL ARTICLE

Membrane Structure Modulation, Protein Kinase Cα Activation, and Anticancer Activity of Minerval

Jordi Martínez, Oliver Vögler, Jesús Casas, Francisca Barceló, Regina Alemany, Jesús Prades, Tünde Nagy, Carmela Baamonde, Philip G. Kasprzyk, Silvia Terés, Carlos Saus and Pablo V. Escribá
Molecular Pharmacology February 1, 2005, 67 (2) 531-540; DOI: https://doi.org/10.1124/mol.104.000778
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results and Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The 73-kDa Heat Shock Cognate Protein Is a CXCR4 Binding Protein that Regulates the Receptor Endocytosis and the Receptor-Mediated Chemotaxis
  • Endogenous Regulator of G-Protein Signaling Proteins Regulate the Kinetics of Gαq/11-Mediated Modulation of Ion Channels in Central Nervous System Neurons
  • A Novel Cyclohexene Derivative, Ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), Selectively Inhibits Toll-Like Receptor 4-Mediated Cytokine Production through Suppression of Intracellular Signaling
Show more ORIGINAL ARTICLE

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics